AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

AxoGen CEO Michael Dale said growth remains focused on expanding the market for peripheral nerve repair. He also noted recent reimbursement wins should be positive, but the financial impact has not yet been quantified. The update is constructive but largely qualitative, with limited near-term price impact.

Analysis

AxoGen CEO Michael Dale said growth remains focused on expanding the market for peripheral nerve repair. He also noted recent reimbursement wins should be positive, but the financial impact has not yet been quantified. The update is constructive but largely qualitative, with limited near-term price impact.